benefits of glp 1 agonists Glucagon-like peptide receptor agonists: cardiovascular and mechanisms action Current Insights, Advantages and Challenges
Description
20 Sochovsky, N
Choi JG, Winn AN, Skandari MR, et al
MACE 4P, 4-point cardiovascular composite episode, including hospitalization due to non-stable angina
While this provides important baseline protection, it leaves gaps: entire drug classes that athletes could test positive for despite using "certified" products
Where Injected GLP-1 Therapies Still Lead Weekly injections such as Wegovy and Mounjaro remain ahead in: Higher average long-term weight-loss percentages More established long-term safety data Real-world evidence across large patient populations Because injections have been studied for over a decade, they currently hold the strongest clinical outcomes in obesity care
Frequently Asked Questions Is Hers a legitimate company
